All for Joomla All for Webmasters

News

St. Louis-Based Precision Virologics Receives $500,000 Investment in Biologically Targeted Vaccines for Zika and Chikungunya

St. Louis, MO (March 29, 2017) – Precision Virologics today announced a $500,000 investment from Oncolys BioPharma, a publicly traded Japanese company focusing on the development of novel viral-based biologics...

Read More

Precision Virologics Enters License Agreement with Washington University to Develop Biologically Targeted Vaccines for Zika and Chikungunya

Saint Louis, MO – March 21, 2017 – Precision Virologics, a biotech company developing biologically targeted vaccines for emerging infectious diseases, today announced that the company has entered a license...

Read More